Seroatlas · Human Serome Atlas

SLA

Src-like-adapter

Also known as: hSLAP, SLA1, SLAP, SLAP-1, SLAP1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q13239
Gene: SLA
Ensembl: ENSG00000155926
Chromosome: 8
Canonical length: 276 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nuclear membrane,Cytosol
Quaternary structure: Homodimer

OverviewNCBI Gene

Predicted to enable epidermal growth factor receptor binding activity and phosphotyrosine residue binding activity. Predicted to be involved in regulation of MAPK cascade and signal transduction. Predicted to be located in cytosol. Predicted to be part of COP9 signalosome. Predicted to be active in cytoplasm; nucleoplasm; and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

276 residues, UniProt reviewed canonical sequence.

>Q13239|SLA
     1  MGNSMKSTPA PAERPLPNPE GLDSDFLAVL SDYPSPDISP PIFRRGEKLR VISDEGGWWK
    61  AISLSTGRES YIPGICVARV YHGWLFEGLG RDKAEELLQL PDTKVGSFMI RESETKKGFY
   121  SLSVRHRQVK HYRIFRLPNN WYYISPRLTF QCLEDLVNHY SEVADGLCCV LTTPCLTQST
   181  AAPAVRASSS PVTLRQKTVD WRRVSRLQED PEGTENPLGV DESLFSYGLR ESIASYLSLT
   241  SEDNTSFDRK KKSISLMYGG SKRKSSFFSS PPYFED

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.46
Highest tissue expression: 146 nTPM

Expression across tissuesHPA

Tissue

thymus: 146 nTPM
bone marrow: 92 nTPM
appendix: 78 nTPM
spleen: 78 nTPM
lymph node: 74 nTPM
tonsil: 67 nTPM

Single-cell type

neutrophils: 1,983 nCPM
monocytes: 464 nCPM
neutrophil progenitors: 432 nCPM
innate lymphoid cells: 331 nCPM
kupffer cells: 327 nCPM
nk-cells: 317 nCPM

Immune cell

neutrophil: 263 nTPM
eosinophil: 204 nTPM
total PBMC: 159 nTPM
non-classical monocyte: 149 nTPM
NK-cell: 133 nTPM
T-reg: 125 nTPM

Brain region

thalamus: 34 nTPM
white matter: 27 nTPM
medulla oblongata: 22 nTPM
cerebral cortex: 21 nTPM
pons: 18 nTPM
spinal cord: 17 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.52
gnomAD pLI: 0.34
gnomAD missense Z: 0.88
DepMap mean gene effect: 0.03
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SLA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLA as an antibody target. Whether an autoantibody or antibody against SLA could matter depends on whether native SLA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SLA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...